Jacobs Levy Equity Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Jacobs Levy Equity Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-17,660	Closed	-$81K	–	1125
2018 Q2	$81K	Sell	17,660 -4,154	-19%	-$21.7K	﹤0.01%	1001
2018 Q1	$157K	Hold	21,814	–	–	﹤0.01%	951
2017 Q4	$156K	Sell	21,814 -1,045	-5%	-$8.84K	﹤0.01%	929
2017 Q3	$190K	Buy	22,859 +3,965	+21%	+$33.6K	﹤0.01%	874
2017 Q2	$193K	Buy	18,894 +12,144	+180%	+$120K	﹤0.01%	849
2017 Q1	$78K	Sell	6,750 -2,130	-24%	-$24.2K	﹤0.01%	873
2016 Q4	$113K	Buy	+8,880	New	+$141K	﹤0.01%	892
2016 Q3	–	Sell	-5,385	Closed	-$57K	–	1200
2016 Q2	$57K	Buy	5,385 +3,130	+139%	+$61.5K	﹤0.01%	1123
2016 Q1	$43K	Buy	+2,255	New	+$43.4K	﹤0.01%	1071

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.01% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jacobs Levy Equity Management's NAVB Position: Q3 2018 in Review

Jacobs Levy Equity Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2018, closing a stake of 17,660 shares — an estimated $81K sold.

Jacobs Levy Equity Management first reported a position in NAVB in Q1 2016 and held it in 9 quarters. The position peaked at $193K in Q2 2017. 52 funds tracked by Wall St. Rank hold NAVB as of Q3 2018.

Jacobs Levy Equity Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 17,660 Navidea Biopharmaceuticals Inc. shares in Q3 2018, an estimated $81K.
Jacobs Levy Equity Management first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2016 and held it in 9 quarters.
Jacobs Levy Equity Management's Navidea Biopharmaceuticals Inc. position peaked at $193K in Q2 2017.
52 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.